LUNAPHORE-TECHNOLOGIES
3.5.2022 11:18:13 CEST | Business Wire | Press release
Lunaphore , a Swiss life sciences company developing technologies to enable spatial biology in every laboratory, today announced that it has deployed its COMET™ PA instrument at Propath UK , one of Europe’s leading contract research organizations (CRO). Propath UK, a specialist in spatial proteomics and transcriptomics, is the first CRO in Europe to offer COMET™ services to researchers and the first organization to join Lunaphore’s Partner Labs Network, a network of CROs and academic core facilities that offer Lunaphore spatial biology solutions as a service to biopharmaceutical and academic researchers.
COMET™ is a strategic investment for Propath UK to expand its spatial biology service offerings with hyperplex staining and imaging, providing its biopharmaceutical research clients with unprecedented insights from tissue samples to answer biological questions. Lunaphore and Propath UK will work closely to provide a flexible service that meets the needs of researchers across various disciplines.
“We are delighted to form this partnership with Lunaphore and be able to offer our biopharmaceutical clients this highly innovative technology for spatial analysis,” said Dr. Krish Soni, Chief Executive of Propath UK. “We look forward to working closely with Lunaphore to help our clients unlock the incredible potential of hyperplex immunofluorescence through our world-class facility dedicated to spatial biology.”
“My team’s previous experience using COMET™ in a variety of applications at the University of Birmingham allowed us to validate the COMET™’s ability to produce staining results of exceptional quality and reproducibility and provided us the confidence to select Lunaphore as Propath’s hyperplex solution partner,” added Kelly Hunter, Chief Scientific Officer at Propath UK.
COMET™ is a fully automated sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases.
“We are excited to partner with Propath UK to expand their spatial biology capabilities,” said Ata Tuna Ciftlik, Chief Executive Officer at Lunaphore. “Propath UK is a highly specialized CRO with spatial biology capabilities who can bring spatial biology solutions to BioPharma. We quickly realized that combining the know-how of the Propath UK team and the versatility of COMET™, with its flexible and streamlined panel development capability using validated antibodies, we will be able to bring outstanding results to the end customers.”
To learn more about the COMET™ PA platform, please visit: https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
To learn more about Propath UK, please visit: https://propath.co.uk
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com .
About Propath UK
Propath UK is a specialist CRO providing research services in molecular pathology, spatial biology and histopathology for the global biopharmaceutical sector. The company offers a range of technologies for spatial proteomic and transcriptomic tissue analysis, including now the Lunaphore COMET™ platform for hyperplex IHC analysis. Propath’s reputation has been gained over the past 40 years by providing a consistent and responsive service across thousands of pre-clinical and clinical studies. To learn more, please visit www.propath.co.uk .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005687/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands Google Relationship with Meridian Integration into NIQ Cadence™30.9.2026 12:30:00 CEST | Press release
Meridian, Google’s open-source Marketing Mix Modeling (MMM), is now available within NIQ Cadence™, accelerating the path from measurement to continuous marketing optimization in one connected workflow. NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the expansion of its relationship with Google through the integration of Meridian, Google's open-source MMM framework, into NIQ Cadence™, NIQ's AI-native marketing effectiveness operating system. The strategic partnership gives marketers a single place to measure marketing performance and act on it, shortening the distance between insights and optimization. Marketing leaders are under growing pressure to prove the return on every media dollar, and traditional measurement has struggled to keep pace. In NIQ’s latest CMO Report, 74% of CMOs said they were under more scrutiny to prove marketing ROI, while just 9% felt they had adequate access to real-time insights. NIQ Cadence™ was built to help close the 65-point acti
Compass Pathways Appoints Kelley Boucher as Chief People Officer30.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psychedelic treatment to the field of psychiatry. In this role, Ms. Boucher will oversee the Company’s people strategy, with an initial focus on guiding its planned evolution towards the launch of COMP360 psilocybin, subject to FDA approval, in the first half of 2027. "We are thrilled to welcome Kelley to our executive team at this pivotal moment in Compass’ journey. As we prepare for our NDA submission in the fourth quarter of this year, we are closer than ever to achieving our goal of introducing an entirely new treatment model in mental health care with COMP360 psilocybin," said Kabir Nath, Chief Executive Officer a
EUMETSAT: Media Invitation30.9.2026 12:17:00 CEST | Press release
Weather in 4D Every 30 Minutes: Europe’s First Geostationary Infrared Sounder Enters Operational Service For the first time, weather forecasters will have access to near-real-time, four-dimensional observations of the atmosphere over Europe every 30 minutes from Europe’s first meteorological infrared sounder in geostationary orbit. EUMETSAT invites media to mark this milestone as the Infrared Sounder (IRS) on board MTG-S1 enters operational service. To mark the occasion, MTG-S1 will also take the name Meteosat-13. The event will showcase the first operational IRS data and EUMETSAT’s 4D weather cube, which combines observations of atmospheric profiles, winds, convection and lightning from three key MTG instruments. Before MTG, only weather models could provide this complete view; now it can be built from real observations and updated every 30 minutes. Journalists will have the opportunity to discover the new data and hear how they can support weather forecasting and the monitoring of ra
Sitetracker Selected by BNZ to Support Scalable Multitechnology Renewable Energy Growth Across Southern Europe30.9.2026 12:07:00 CEST | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced that BNZ, an independent power producer (IPP) focused on renewable energy across Southern Europe, has selected Sitetracker to streamline and scale the management of its growing multitechnology portfolio. BNZ develops, builds, and operates utility-scale renewable energy assets across Spain, Italy, and Portugal. Its portfolio exceeds 2.7 GW across development, construction, and operation, including 530 MW connected and 222 MW under construction. To support its continued growth, BNZ sought a centralized platform to improve visibility, standardize workflows, and strengthen operational efficiency across the full asset lifecycle. “The next generation of renewable energy leaders will be defined by how efficiently they can scale,” said Giuseppe Incitti, CEO of Sitetracker. “BNZ is taking a proactive approach to building the operational infrastructure needed to support long-term gr
Linesight Appoints John Butler as CEO30.9.2026 12:00:00 CEST | Press release
Paul Boylan continues to lead the wider IPS group as CEO Linesight, the global construction consultancy, today announced the appointment of John Butler as Chief Executive Officer, effective 1 January 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930482486/en/ John Butler, incoming CEO of Linesight (left), and Paul Boylan, Group CEO of IPS-Integrated Project Services, LLC (right). Butler will become CEO of Linesight effective 1 January 2027, succeeding Boylan, who will continue to lead the wider group. Butler will succeed Paul Boylan, who will remain closely involved with Linesight and its clients as Group CEO of IPS-Integrated Project Services, LLC (IPS). Boylan will continue to lead this wider group, encompassing IPS, Linesight and Springtide. Today, the group comprises of more than 4,500 people and generates approximately $2 billion in net revenue, providing multi-sector solutions through its specialist brands. L
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom